Nutraveris
Monday, January 8, 2018
Category : NEWS, CLAIMS, INGREDIENTS | Author : experts | Comment : No Comments
Tags:

Thanks to its substantial experience in the novel food process and management in Europe, Nutraveris has just obtained a new success further to the recognition by the European Food Safety Authority (EFSA) that the orthosilicic acid-vanillin complex (OSA-VC) is safe for human consumption.

EFSA’s opinion comes after a complete evaluation of the application in accordance with the previous novel food regulation (regulation (EC) No 258/97). The ingredient, a dietary source of silicon, has been evaluated by Member States and by EFSA, with deep and important discussions on all the aspects of a novel food application (i.e. characterization of the ingredient, bioavailability and safety).

efsa

 

This new success for Nutraveris confirms its position as a leading consultancy in the European novel food approval.

Nutraveris has indeed all the skills and experience to obtain EU authorizations.

 

Do not hesitate to contact our Scientific & Regulatory experts for further information at NUTRAVERIS

Hotline Nutraveris: +33 2 96 76 54 87 , contact@nutraveris.com

 

Thursday, January 4, 2018
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

This publications reports the results of two randomized, double-blinded and placebo-controlled trials assessing the acute effects of oral ATP in recreationally trained men (n = 11). The supplementation consisted in a single dose of 400 mg of ATP. 30 min after its consumption, participants performed an exercise session (4 sets) in order to measure the effects of ATP on performance and physiological responses during resistance exercise.

 

physical performances

 

The total weight lifted were higher for the ATP condition compared to placebo (placebo = 3995.7 ± 1137.8, ATP = 4967.4 ± 1497.9 Kg; p= 0.005). Heart rate was higher at set-4 for ATP compared to placebo (p < 0.001) and oxygen consumption during exercise was greater for ATP (p = 0.021). Conversely, there were no differences between conditions for lactate and blood pressure.

Therefore, a single dose of ATP exhibits acute effects on performance in recreationally trained men.

 

 Freitas MC, Cholewa JM, Gerosa-Neto J, Gonçalves DC, Caperuto EC, Lira FS, Rossi FE. A Single Dose Of Oral Atp Supplementation Improves Performance And Physiological Response During Lower Body Resistance Exercise In Recreational Resistance Trained Males. J Strength Cond Res. 2017 Oct 16.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, January 2, 2018
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

Cranberry has been advocated for treatment of urinary tract infection. It appears its efficacy remains controversial.

 Cranberry

This meta-analysis has been conducted to assess the effect of cranberry on the risk of urinary tract infection recurrence in otherwise healthy women. To do so, the literature published until June 2017 was examined to identify pertinent studies to include.  All of randomized controlled trials studies has been included if they enrolled healthy non pregnant women aged >18 years with a history of urinary tract infection and which compared cranberry intervention to placebo or control. The outcome “number of participant experiencing a urinary tract infection” had to be reported. Screening and data extraction have been done by the two same researchers.

They identified 7 randomized controlled trial conducted in the right population (n= 1498 healthy women with urinary tract). Results of the meta-analysis showed that cranberry reduced the risk of urinary tract infection by 26 % (pooled risk ratio: 0.74; 95 % CI 0.55, 0.98; I²= 54 %)

 

The authors conclude that results suggest that cranberry may be effective in preventing urinary tract infection recurrence in generally healthy women.

 

       

Fu Z, Liska D, Talan D, Chung M, Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr. 2017 Oct 18. pii: jn254961

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, December 28, 2017
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

The purpose of this paper is to investigate the effect of probiotic Lactobacillus casei Shirota on patients with knee osteoarthritis.

Lactobacillus casei Shirota 

 

This study was a randomized, double-blind, placebo-controlled study. To do so, 537 patients with knee osteoarthritis were enrolled and received skimmed milk containing either Lactobacillus casei Shirota or placebo daily for 6 months.

Primary outcome was defined as changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and visual analog scale (VAS) scores. Secondary outcome was defined as changes in serum levels of high sensitivity C-reactive protein (hs-CRP).

The main results show after 6 months a significantly improvement of both WOMAC and VAS score in the Lactobacillus casei Shirota group compared to the placebo group. Moreover, serum levels of hs-CRP levels were also significantly improved in the Lactobacillus casei Shirota consumption.

 

To conclude, the main findings of this clinical study were a daily dose of 1.2×1010 cfu Lactobacillus casei Shirota could improve treatment outcome of knee osteoarthritis, possibly by reducing serum levels of hs-CRP, an inflammation response factor frequently elevated in musculoskeletal disorders.

       

Lei M, Guo C, Wang D, Zhang C, Hua L, The effect of probiotic Lactobacillus casei Shirota on knee osteoarthritis: a randomised double-blind, placebo-controlled clinical trial. Benef Microbes. 2017 Oct 13;8(5):697-703

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, December 26, 2017
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This meta-analysis was performed to assess the efficacy and safety of turmeric and curcumin in lowering blood lipids in patients at risk of cardiovascular disease (CVD). The analysis included 7 eligible studies (649 patients).

 

Turmeric and curcumin in lowering blood lipid levels

 

Turmeric and curcumin significantly reduced serum LDL-C (SMD = -0.340, 95% confidence interval [CI]: -0.530 to -0.150, P < 0.0001) and TG (SMD = -0.214, 95% CI: -0.369 to -0.059, P = 0.007) levels as compared to those in the control group.

These may be effective in lowering serum TC levels in patients with metabolic syndrome (MetS, SMD = -0.934, 95% CI: -1.289 to -0.579, P < 0.0001), and turmeric extract could possibly have a greater effect on reducing serum TC levels (SMD = -0.584, 95% CI: -0.980 to -0.188, P = 0.004); however, the efficacy is yet to be confirmed. Serum HDL-C levels were not obviously improved. Turmeric and curcumin appeared safe, and no serious adverse events were reported in any of the included studies.

 

Authors concluded turmeric and curcumin may protect patients at risk of CVD through improving serum lipid levels.

 

Qin S, Huang L, Gong J, Shen S, Huang J, Ren H, Hu H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017 Oct 11;16(1):68

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87